Adult Dosing
Treatment and prevention of osteoporosis in postmenopausal women; reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis or those at high risk of invasive breast cancer
Note:
- Provide adequate calcium (1500 mg/day) and/or vitamin D (400-800 IU/day) supplementation in postmenopausal women for the treatment or prevention of osteoporosis
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
[Outline]
See Supplemental Patient Information
- Contraindicated in women with active or past history of venous thromboembolism. Higher incidences of deep vein thrombosis and pulmonary embolism have been reported with therapy [US Black Box Warning]
- The risk for DVT and pulmonary embolism is greatest during the first 4 months of treatment. Superficial thrombophlebitis has also been frequently reported
- Discontinue therapy 72 hrs prior to and during prolonged immobilization and re-initiate only after the patient is fully ambulatory
- Risks and benefits should be evaluated in women at risk of thromboembolism for other reasons such as congestive heart failure, superficial thrombophlebitis, and active malignancy
- Risk of death due to stroke may be increased in postmenopausal women with coronary heart disease or at increased risk for coronary events [US Black Box Warning]
- Consider risk-benefit balance in women who are at risk for stroke (prior stroke or transient ischemic attack, atrial fibrillation, hypertension, or cigarette smoking)
- Do not use for primary or secondary prevention of cardiovascular disease
- Not recommended for use in premenopausal women
- Women with a history of marked hypertriglyceridemia in response to treatment with oral estrogen or estrogen plus progestin may develop increased triglyceride levels with raloxifene therapy. Regular monitoring of triglyceride levels is recommended in these patients
- Not recommended for use in men
- Investigate any unexplained uterine bleeding during therapy
- Investigate any unexplained breast abnormality occurring during therapy, as raloxifene does not eliminate the risk of breast cancer
Cautions: Use cautiously in
- Moderate or severe renal impairment
- Hepatic impairment
- History of breast cancer
Supplemental Patient Information
- Advise patients to consider weight-bearing exercises along with modification of certain behavioral factors, such as cigarette smoking and excessive alcohol consumption
- Instruct patients to avoid prolonged restrictions of movement during travel due to increased risk of venous thromboembolic events
- Advise patients to have breast exams and mammograms prior to and regularly during treatment consistent with good medical practice after beginning raloxifene therapy
Pregnancy Category:X
Breastfeeding: Safety unknown; contraindicated in nursing women.
Pricing data from www.DrugStore.com in U.S.A.
- Evista 60 MG TABS [Bottle] (LILLY)
30 mg = $149.99
90 mg = $419.95
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
Drug Name: Evista 60 MG Oral Tablet
Pill Image:
[
See full size image]
Ingredient(s): Raloxifene
Imprint: LILLY;4165
Color(s): White
Shape: Oval
Size (mm): 12.00
Score: 1
Inactive Ingredient(s): carnauba wax / crospovidone / hypromellose / lactose monohydrate / anhydrous lactose / magnesium stearate / polyethylene glycol / povidone / titanium dioxide / polysorbate 80 / propylene glycol
Drug Label Author:
Eli Lilly and Company
DEA Schedule:
Non-Scheduled
